drugset / Trial / NCT07339527
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of EZH2 inhibitor Zeprumetostat in combination therapy for patients with relapsed or refractory mature T-cell and NK-cell lymphomas.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2028-01-01
- Completion
- 2030-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | 150 mg | Oral |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |
| Subject | Zeprumetostat | Small molecule | 350 mg | Oral |